Correction: Editorial: Current status and recent advances in preclinical models for rare cancers

Krawczyk, Ewa; Cavalli, Luciane R.; Kitlinska, Joanna

doi:10.3389/fonc.2025.1697286

CORRECTION article

Front. Oncol., 23 September 2025

Sec. Cancer Molecular Targets and Therapeutics

Volume 15 - 2025 | https://doi.org/10.3389/fonc.2025.1697286

Correction: Editorial: Current status and recent advances in preclinical models for rare cancers

This article is a correction to:

Editorial: Current status and recent advances in preclinical models for rare cancers
1. Read original article

Ewa Krawczyk^1*

Luciane R. Cavalli^2,3

Joanna Kitlinska⁴

¹Department of Pathology, Georgetown University Medical Center, Washington, DC, United States
²Instituto de Pesquisa Pele Pequeno Principe, Curitiba, Brazil
³Department of Oncology, Georgetown University Medical Center, Washington, DC, United States
⁴Department of Biochemistry and Molecular & Cellular Biology, Georgetown University Medical Center, Washington, DC, United States

A Correction on
Editorial: Current status and recent advances in preclinical models for rare cancers

By Krawczyk E, Cavalli LR and Kitlinska J (2025). Front. Oncol. 15:1676020. doi: 10.3389/fonc.2025.1676020

Affiliation “Department of Oncology, Georgetown University Medical Center, Washington, DC, United States” was omitted for author Luciane R. Cavalli. This affiliation has now been added for author Luciane R. Cavalli.

Affiliation “Department of Biochemistry and Molecular & Cellular Biology, Georgetown University Medical Center, Washington, DC, United States” was omitted for author Joanna Kitlinska. Erroneously given as “Department of Pathology, Georgetown University Medical Center, Washington, DC, United States.

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: rare cancers, cancer models, preclinical disease models, translational cancer research, in vitro cancer models, in vivo cancer models

Citation: Krawczyk E, Cavalli LR and Kitlinska J (2025) Correction: Editorial: Current status and recent advances in preclinical models for rare cancers. Front. Oncol. 15:1697286. doi: 10.3389/fonc.2025.1697286

Received: 02 September 2025; Accepted: 05 September 2025;
Published: 23 September 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Krawczyk, Cavalli and Kitlinska. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Ewa Krawczyk, ZXdhLmtyYXdjenlrQGdlb3JnZXRvd24uZWR1

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.